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a b s t r a c t
An understanding of the thermodynamics of the complexation process utilized in sustaining drug release
in clay matrices is of great importance. Several characterisation techniques as well as isothermal calo-
rimetry were utilized in investigating the adsorption process of a model cationic drug (diltiazem hy-
drochloride, DIL) onto a pharmaceutical clay system (magnesium aluminium silicate, MAS). X-ray
powder diffraction (XRPD), attenuated total reﬂectance Fourier transform infrared spectroscopy (ATR-
FTIR) and optical microscopy conﬁrmed the successful formation of the DIL-MAS complexes. Drug
quantiﬁcation from the complexes demonstrated variable behaviour in the differing media used with DIL
degrading to desacetyl diltiazem hydrochloride (DC-DIL) in the 2 M HCl media. Here also, the authors
report for the ﬁrst time two binding processes that occurred for DIL and MAS. A competitor binding
model was thus proposed and the thermodynamics obtained suggested their binding processes to be
enthalpy driven and entropically unfavourable. This information is of great importance for a formulator
as care and consideration should be given with appropriate media selection as well as the nature of
binding in complexes.
© 2019 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Minerals have a variety of applications in the pharmaceutical
industry and in medicine which date back since prehistory [1].
Minerals have desirable physicochemical properties such as
chemical inertness, high adsorption capacity and speciﬁc area,
swelling, water solubility and dispersivity, plasticity, acid-
absorbing capacity, as well as colour, opacity and low or no
toxicity in patients, which makes them suitable for medical and
pharmaceutical applications [1,2]. In the formulation of pharma-
ceutical dosage forms, minerals are used as excipients as carriers of
active ingredients to achieve modiﬁed release, or as binders, ﬁllers,
disintegrants, lubricants, thickening agents, anticaking agents, ﬂa-
vouring correctors and emulsifying agents [2].
Magnesium aluminium silicate (MAS or VEEGUM®) is a mixture
of natural smectite montmorillonite and saponite clays (Fig.1). MAS
has a layered silicate structure, formed of one alumina or magnesia
octahedral sheet, sandwiched between two tetrahedral silicate
sheets [3,4]. The high surface area and good afﬁnity with cationic
drugs, as well as its non-toxic properties make MAS a suitable
material for use in drug formulation. MAS has previously been
shown to be able to adsorb cationic drugs such as propranolol hy-
drochloride and form complexes that are able to retard drug release
[5e7]. Controlling drug release is of high interest as it has been
demonstrated to show many beneﬁts compared with conventional
drug release. By maintaining a constant drug-plasma concentration
for extended periods of time, it is possible to achieve optimal efﬁ-
cacy in chronic conditions where medication must be administered
at constant levels, and reduce the side effects [8]. The use of a
model drug such as diltiazem hydrochloride (DIL), in combination
with magnesium aluminium silicate to achieve controlled drug
release, adds value to the importance of using clay minerals as drug
carriers [5,6,9].
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DIL is a non-dihydropyridine calcium channel blocker. It inhibits
the calcium channels in the blood vessels, which leads to vasodi-
latation and, hence, to a lower blood pressure. Furthermore, DIL
inhibits calcium channels in the heart, leading to a reduced cardiac
contractility and a slower atrioventricular conduction velocity
[10,11]. Therefore, DIL represents an efﬁcient treatment for patients
suffering from stable chronic angina, due to its ability to reduce
myocardial oxygen demand, as it lowers blood pressure, heart rate
and cardiac contractility. The drug can also be efﬁciently used in
treating arterial ﬁbrillation due to its ability to control heart rate
through its capability to reduce atrioventricular node conduction.
DIL’s critical drawbacks include an elimination half-life of
3.2 ± 1.3 h following oral administration, and a bioavailability of
(42 ± 18)% following ﬁrst pass metabolism [12]. Therefore, in order
to acquire its therapeutic effects and to maintain adequate drug
plasma levels, it needs to be administered frequently (3e4 times/
day) [13,14]. This model drug therefore represents a suitable target
for an extended release formulation. Using clay, instead of the
traditionally adopted polymers to control drug release, brings
multiple beneﬁts such as overall reduced costs and antibacterial
effects, as well as improved kinetics of drug release. This study
therefore aims to understand and fully characterise the complexes
that are formed between the MAS and DIL that provide the
controlled release effect as well as using complex software in un-
derstanding the thermodynamics associated with this process.
2. Experimental
2.1. Materials
VEEGUM F EP® (MAS) was a kind gift from R. T. Vanderbilt
Company, Norwalk, CT (USA). DIL (MW ¼ 450.98, pKa ¼ 7.8 ± 0.4)
was purchased from TCI (Tokyo Chemical Industry), Tokyo. Aceto-
nitrile (HPLC grade) and sodium phosphate, dibasic hydrate, 99þ%
(HPLC grade), 2 M sodium hydroxide and 2 M hydrochloric acid
were purchased from Fisher Scientiﬁc, UK.
2.2. Methods
2.2.1. Microscopy studies and formulation of MAS-DIL complex
particles
Digital microscopy was used to observe the formation of ﬂocs
upon the addition of dilute DIL solution to dilute MAS dispersion
(ratio 0.5:1, w/v). The drug to clay ratio used in this study was
chosen based on the assay studies presented in Section 3.1. This
showed the amount of DIL adsorbed onto the clay was maximum
0.26 g DIL/1 g of MAS. Studies were performed using a VHX2000
Digital Microscope from KEYENCE using a blue daylight ﬁlter to
enhance the contrast between the ﬂocculated particles and the
dispersion media. Pictures were recorded at different mixing time
points (2 min, 30 min, 60 min, 120 min,180min and 24 h) and were
compared. Images of the MAS dispersion prior to DIL additionwere
also acquired.
For the formulation process, MAS-DIL complex particles were
prepared by loading the MAS with DIL twice in order to ensure a
high drug adsorption. For the ﬁrst drug loading, separate DIL so-
lution (2%, w/v) andMAS dispersion (2%, w/v) were prepared under
continuous stirring for 24 h at 500 rpm (25 C). The pH of the
prepared MAS dispersion and DIL solution was adjusted to pH 5
using 2 M hydrochloric acid and 2 M sodium hydroxide. After 24 h,
the MAS dispersion and DIL solutionwere combined (1:1, w/w) and
the mixture was incubated at 37 C with shaking for 24 h. Floccu-
lates were observed in the mixture. The MAS-DIL complex disper-
sions obtained were then ﬁltered using a Buchner ﬁltration
apparatus with vacuum. For the second drug loading, previously
ﬁltered single drug loaded MAS-DIL complex particles were redis-
persed into a fresh DIL solution (2%, w/v) and incubated at 37 C
with shaking for 24 h. The MAS-DIL ﬂocculated complexes formed
were ﬁltered and dried in the oven at 50 C for 48 h. The dried
double drug loaded MAS-DIL complex particles were ground
(10 min) using a Retsch® PM 100 ball mill set at 350 rpm to particle
sized at 123e65 mm. The use of the ball mill led to a faster break-
down of the hard particulates to the desired particle size.
2.2.2. Characterisation of MAS-DIL complex dispersions and
particles
2.2.2.1. Attenuated total reﬂectance Fourier transform infrared spec-
troscopy (ATR-FTIR). ATR-FTIR was used to study the interaction
betweenMAS and DIL at themolecular level. MAS, DIL andMAS-DIL
complex particles were analysed from 4000 to 400 cm-1 on a Smart
Orbit ATR-FTIR machine, using diamond as the ATR crystal.
2.2.2.2. Powder X-ray diffractometry (PXRD). Experiments were
performed on a D2 PHASER XRD from BRUKER and sample prep-
aration involved the placement of sample powder onto a trans-
mitter holder and conducted using a similar methodology as
reported [15]. Analysis was performed at an angular range 2.5e70
(2q) and a step angle of 0.02 (2q) s-1. The X-ray source was
generated as a Cu radiation at 30 kV and 10 mA. Experiments were
performed in triplicate for reproducibility.
2.2.3. High performance liquid chromatography (HPLC)
An HPLC method was developed and validated for the deter-
mination and quantiﬁcation of both DIL and its main degradant,
desacetyldiltiazem (DC-DIL) which was observed in samples.
Linearity range, precision, limit of quantitation (LOQ) and limit of
detection (LOD) were separately determined for both compounds
(DIL and DC-DIL) to validate the method used. The peak area of the
standards along with the corresponding drug concentration was
used to generate a calibration graph to evaluate linearity (slope,
intercept and coefﬁcient of determination R2) and determine LOD
and LOQ. All experiments were conducted in triplicate. An assay of
Fig. 1. Montmorillonite (A) and saponite (B) clay structure showing the magnesia or alumina octahedral sheet trapped between two tetrahedral silicate sheets: adapted from [4].
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freshly prepared standard DIL and DC-DIL solutions at four different
concentrations (1.00, 10.00, 50.00 and 100.00 mg/mL and 0.83, 8.25,
41.26, 82.52 mg/mL respectively) repeatedly run on the same day or
on three different days was used to evaluate the intra- and inter-
day precision in terms of standard deviation RSD %.
DIL stock solution and standard solutions in the range 100 to
0.1 mg/mL were prepared in puriﬁed water. DC-DIL was formed
from DIL via hydrolysis (Fig. 2). DIL stock solution was prepared in
dilute acid (2 M HCl) and standard solutions in the range 75 to
0.1 mg/mL were prepared from the stock solution using puriﬁed
water. Samples were left for 72 h at room temperature until com-
plete hydrolysis occurred (conﬁrmed by HPLC). The concentration
of DC-DIL present in the standards was determined from the
equilibrated hydrolysis reaction assuming that 100% of the drug
hydrolysed was observed, as no traces of the parent drug were
observed in solution.
The calibration graphs generated for DIL and DC-DIL were found
to be linear over the concentration range studied (1.00, 10.00, 50.00
and 100.00 mg/mL and 0.83, 8.25, 41.26 and 82.52 mg/mL, respec-
tively) (R2  0.9999 and R2  0.9998, respectively). Linearity was
deﬁned by an equation that was further used in the recovery
studies. The method was shown to be precise for the detection of
both DIL and DC-DIL, the intermediate and intra-assay precision at
four different concentrations on three different days being lower
than 2% RSD (Table 1) which complies with the acceptable criteria
for quality control of pharmaceutical preparations [16,17]. LOQ (the
lowest drug concentration that can be recovered within acceptable
limits of precision and accuracy) was found to be 1.72 mg/mL for DIL
and 1.65 mg/mL for DC-DIL, indicating the high sensitivity of the
proposed method at low concentrations of DIL and DC-DIL. LOD
(the lowest detectable amount of drug distinguishable from the
blank) was 0.57 mg/mL for DIL and 0.55 mg/mL for DC-DIL, con-
ﬁrming the sensitivity of the method proposed.
2.2.4. Isothermal titration calorimetry (ITC)
ITC was used to investigate the binding between MAS and DIL.
Single injections experiment (SIM) and multiple injection experi-
ments (MIM) were performed. The fast titration and versatile SIM
experiments were used to initially conﬁrm binding and determine
the nature of the interaction, while MIM experiments were used
further to characterise the reaction in detail and determine the
thermodynamic parameters. Studies were carried out on a Microcal
VP ITC micro-calorimeter. The instrument was used in high-gain
mode, applying a reference power of 20 mcal s-1 whilst stirring
the sample cell contents at 307 rpm. TheMAS dispersionwas added
into the sample cell and DIL solution into the syringe for all the
experiments.
SIM experiments were performed at three different pH values,
i.e., 5, 7 and 9 (25 C). DIL solution was added in one injection into
the sample cell. The SIM experiments were fast titration experi-
ments and the real time binding isotherm observed was analysed
using Origin 7.0 (MicroCal, Inc) by comparing the reaction rate at
the pH values studied [18].
0.010% (w/v) MAS dispersion was prepared under continuous
stirring for 24 h, at 25 C and 200 rpm and was used to ﬁll the
sample cell. A 1 mM DIL solution was also prepared separately
under stirring for 30 min at 25 C and 200 rpm prior to the ex-
periments and was independently used to ﬁll the syringe. The drug
solution was added as 1 injection of 250 mL into the sample cell
containing MAS. The pH of the prepared solutions and dispersions
were adjusted using 2 M hydrochloric acid and 2 M sodium hy-
droxide to 5, 7 and 9. All experiments were conducted in triplicate.
MIM ITC studies were carried out at 25 C and pH 5, at two
different DIL and MAS concentrations. The binding isotherm was
studied in 120e140 injections of 2 mL each into the sample cell
every 260 s. MAS dispersion (0.036% and 0.010%, w/v) and DIL so-
lution (3.2 mM and 0.45 mM) were prepared. A competitor binding
model (Fig. 3) was ﬁtted to the data to get thermodynamic pa-
rameters which best reproduce the experimental data using
AFFINImeter (AFFINImeter, Spain). The total molar concentration of
MAS was estimated and the relative molar fractions of each kind of
clay (rb, rm) were considered unknown and set as ﬁtted parameter
in the analysis.
rb$[B] þ rm$[M] ¼ [MAS]
3. Results and discussion
3.1. Observation of ﬂoc formation and drug content analysis from
MAS-DIL double drug loaded complex particles
The initial analysis of the MAS dispersion using digital micro-
scopy (Fig. 4) allowed the observation of small clay particles
dispersed in water forming a colloidal structure, described in
literature as the ‘house of cards’ [4] through the attraction between
the negatively charged faces and the partially positive edges of the
clay platelets (Fig. 4 A). Following the addition of DIL, the initially
monodispersed particles started aggregating as ﬂocs (forming after
only 2 min) (Fig. 4 D). With time, ﬂocs were observed to increase in
size, became more porous and spread out as the particles clustered
together (Figs. 4EeG). After 24 h, a decrease in the size of the
ﬂocculated clustered particles was observed as loosely bound ag-
gregates separated away and reattached to other aggregates in a
more stable form (Fig. 4HeJ) [19]. This process allows the interca-
lation process to occur after which drug entrapment can be
determined.
Determination of drug content in the MAS-DIL double drug
loaded complex particles prepared as described in Section 2.2.1
showed discrepancies between the different media used for the
dispersion of the complex particles (Table 2). The difference can be
related to the behaviour of DIL andMAS in the dissolutionmedia, as
well as to the mechanism of adsorption of DIL onto MAS. Results
showed that only DC-DIL was recovered by dispersing the MAS-DIL
particles in 2 M HCl (Table 2). The degradant was identiﬁed
following a shift in the retention time on the chromatograms from
approx. 7 min (DIL standard solution), to approx. 3.8 min (recov-
ered DIL) (Fig. 5). This behaviour was attributed to the hydrolysis of
DIL under acidic conditions and the peak was identiﬁed as being
DC-DIL, the main degradant of DIL [16,20,21]. A reduction in the
exposure time of the MAS-DIL complex to the acid solution from
24 h to 30 min allowed the observation of the two peaks belonging
to DIL and DC-DIL on the same chromatogram (Fig. 5B).
Further studies evaluating DIL content in MAS-DIL double drug
loaded complex particles by dispersing the particles in ultra-pure
water (pH 5) and phosphate buffer (pH 6.8) showed aFig. 2. DIL undergoing dilute acid hydrolysis and product desacetyldiltiazem.
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considerable reduction of DIL degradation. The results showed less
than 10% of DIL recovered from the complexes hydrolysed over 24 h
in water and phosphate buffer, hence conﬁrming the effect of 2 M
HCl on DIL leading to degradant DC-DIL.
3.2. Solid state characterisation
3.2.1. ATR-FTIR
ATR-FTIR was used to study the adsorption of DIL onto MAS
based on the vibration of chemical bonds formed (Fig. 6). Charac-
teristic peaks were observed on the spectrum of MAS such as the
hydroxyl group belonging to SieOH at 3625 cm-1 and the SieOeSi
stretching at 980 cm-1, as well as peaks related to water residues
(OeH stretching 3415 cm-1) and water of crystallisation (OeH
group bending at 1640 cm-1) [6,7].
The spectrum of MAS-DIL double drug loaded complexes was
very different from that of DIL alone, but similar to that of MAS. The
Table 1
HPLC method validation for DIL and DC-DIL showing intermediate and intra assay precision at four different concentrations.
Compound Concentration (mg/mL) Intermediate precision (RSD, %) Intra-assay precision (RSD, %)
DIL 1.00 5.32 1.67
10.00 0.85 0.48
50.00 0.65 0.17
100.00 0.55 0.16
DC-DIL 0.83 1.26 0.63
8.25 0.52 0.91
41.26 0.25 0.39
82.52 0.38 0.63
Fig. 3. Competitive ligand binding where A is the ligand in the syringe (DIL) (A), and M
and B are the macromolecule and competitive ligand respectively (montmorillonite
and saponite making up the MAS), both present in the sample cell (B), (C) proposes the
how ligand A binds to receptors B and M.
Fig. 4. Scheme of the ‘house of cards’ formed upon MAS dispersion in water: adapted from Ref. [4] (A); Digital microscopy images of MAS (B); Chemical representation of DIL
structure (C); and complexes formed between MAS and DIL at different time points of aggregation (DeJ).
Table 2
DIL and DC-DIL content in double drug loaded MAS-DIL complex particles.
Media Recovered DIL (% w/w) Recovered DC-DIL (% w/w)
2 M HCl n/a$ 25.78 ± 0.32*
Ultra-pure water 16.48 ± 0.42* 1.31 ± 0.03*
pH 6.8 phosphate buffer 17.61 ± 0.22* 1.55 ± 0.02*
$DIL completely degraded, hence only degradant DC-DIL recovered.
Note: *values are reported as mg of drug per g MAS.
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presence of the SieOeSi stretching belonging to the clay was still
observed as a broad peak at 980 cm-1. A peak attributed to the
hydroxyl stretching of the SieOH group was observed at 3631 cm-1.
The C]O carbonyl groups belonging to DIL at 1680 cm-1 and
1740 cm-1 and C]C aromatic ring stretching belonging to DIL at
1511 cm-1 were still observed but all became smaller. The peak
belonging to the amine group on the DIL structure observed at
1217 cm-1 was still present but became broader. The peaks attrib-
uted to ReOeR stretching at 1026 cm-1 and CeO ester stretching at
1059 cm-1 on DIL structure were not observed on the spectrum of
MAS e DIL complex particles. The change and disappearance of
some of the peaks characteristic to both DIL andMAS demonstrated
the potential interaction between them by the formation of
hydrogen bonds between the silanol groups of MAS with the amine
and hydroxyl groups of DIL [6,7].
3.2.2. PXRD
The diffractogram acquired for MAS (Fig. 7) displays a distinctive
reﬂection at 6.87034 (2q) representing the thickness of the basal
spacing between the platelets, calculated using Bragg’s Law as be-
ing 1.28 nm, a value similar to those suggested in the literature
[6,9]. The prepared MAS-DIL complex particles were shown to be in
amorphous form and did not follow the PXRD pattern of DIL or MAS
alone. The amorphous characteristic of the MAS-DIL sample sug-
gests the molecular dispersivity of the drug in the prepared com-
plexes. Furthermore, the reﬂection at 6.87034 (2q) on the MAS
diffractogram representing the basal spacing was shifted to
4.382592 (2q) on the MAS-DIL diffractogram and showed a
reduced intensity. The peak shift means an increase in basal spacing
of MAS from 1.28 nm up to z2.016 nm upon intercalation of DIL
into the clay platelets, hence conﬁrming the complexation [6,22].
3.3. ITC
3.3.1. Binding between MAS and DIL: single injection experiments
SIM experiments conﬁrmed that binding occurred between
MAS and DIL. The binding isotherm between MAS and DIL was
Fig. 5. Typical HPLC chromatograms of: DIL standard solution at 25 C (A) and DIL recovered from MAS-DIL complex using 2 M HCl (24 h exposure) (B), 2 M HCl (30 min exposure)
(C), ultra e pure water (D) and pH 6.8 phosphate buffer (E) showing the presence of DIL (1) and degradant desacetyl diltiazem (2).
Fig. 6. ATR-FTIR for DIL, MAS and MAS-DIL double drug loaded complex.
Fig. 7. PXRD patterns of MAS, DIL and MAS-DIL double drug loaded complexes.
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shown to be highly exothermic at the pH values studied (Fig. 8). The
power signal returned to baseline faster at pH 9 compared with pH
5 and 7, indicating therefore a more rapid interaction. Considering
the ionisation of DIL, a more favourable interaction at pH 9 implies
that DIL is more readily adsorbed onto MAS via hydrogen bonding
and water bridging, the drug being mainly present in solution in its
unionised form at this pH. This may be explained by the increased
length of the alkyl ammonium chain and large molecular weight of
DIL, which were shown to result in a greater contribution to
adsorption onto the clay via van der Waals forces in previous
studies [23,24].
3.3.2. Binding between MAS and DIL: multiple injection
experiments
The binding between MAS and DIL was further explored using
MIM stepwise experiments at pH 5 and 25 C. The working pH was
chosen based on drug ionisation, DIL being mostly ionised in so-
lution at pH 5 (pKa 7.8) and hence, expected to interact with the
negatively charged faces of MAS platelets [4,25]. Experiments
conﬁrmed the binding and showed the presence of more than one
binding event at both higher and lower concentrations (Figs. 9 A
and B). The experiment at low concentration (Fig. 9 B) allowed the
highly detailed observation of the binding events, conﬁrming that
there were no other additional processes taking place. Control
binding experiments showed no interaction between MAS disper-
sion and water, and between DIL solution and water at pH 5 and
25 C. The presence of multiple binding events following MAS-DIL
binding was not observed in the ITC SIM experiments, hence
emphasising the importance of MIM stepwise experiments in
describing chemical interactions in detail.
A competitor binding model (Fig. 10) was ﬁtted to the data to
determine the thermodynamic parameters of the reaction. For this
analysis it was assumed that the two different types of clay within
MAS (montmorillonite and saponite) placed into the sample cell
may potentially interact differently upon the addition of DIL. This
assumption was made based on the isomorphic substitution of a
limited amount of octahedral Al3þ with Mg2þ in montmorillonite
and the substitution of a limited amount of tetrahedral Si4þ by Al3þ
in saponite, naturally balanced by exchangeable Naþ ions that can
be easily displaced and replaced, giving the clay the ability to act
like a reservoir. Initially the concentrations of both clays were
considered equal to total MAS, that is, [B] ¼ [M] ¼ [MAS] and
AFFINImeter was used to ﬁt the data with the competitive model
using rb and rm (the correction of the nominal concentration of the
compounds in the cell) as ﬁtted parameters with the following
constraint rb þ rm ¼ 1. The ﬁtting of rb and rm allows the calcu-
lation of the real concentration of both kinds of clay. The analysis
revealed that approximately 24% of theMAS interacts strongly with
DIL (Ka ¼ 2.54 Eþ7 ± 1.10 Eþ6 M) and 76% of MAS interacts weakly
with DIL (Ka¼ 4.80 Eþ5 ± 7.59 Eþ3M) (Table 3). The binding events
had similar negative enthalpies (6.71 Eþ3 ± 1.29 Eþ1 cal/mol
and 8.94 Eþ3 ± 2.18 Eþ1 cal/mol) and negative
entropies 9.28Eþ2 cal/mol and 1.02Eþ3 cal/mol (Table 3), sug-
gesting that in both cases the binding was enthalpy driven and
entropically unfavourable, as high energy resulted from broken and
created hydrogen bonds as well as electrostatic van der Waals in-
teractions. This implies that montmorillonite and saponite are able
to adsorb DIL through a similar mechanism due to their similar
structure. The presence of the two binding events upon the
adsorption of a cationic compound ontoMAS has not been reported
in literature before.
4. Conclusions
DIL and MAS complexes which can be used in providing oral
controlled release formulation or strategies were successfully made
and characterised. The process of binding revealed two binding
processes that are being reported for the ﬁrst time for DIL andMAS.
The thermodynamics suggested that the binding processes for
these two events were enthalpy driven and entropically unfav-
ourable. The quantiﬁcation of these complexes also revealed
Fig. 8. Titration of DIL solution (pH 5) into MAS dispersion (pH 5) (black), pH 7 (red)
and pH 9 (green) at 25 C.
Fig. 9. ITC raw data showing: titration of 3.2 mM DIL into 0.036% MAS and blank titrations (water into MAS 0.036% (w/v) and DIL 3.2 mM into water) (A); titration of 0.45 mM DIL
into 0.010% (w/v) MAS (B). All experiments were undertaken at pH 5 and 25 C.
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variable behaviour in the various media tested which can inform a
formulator decision in appropriate media for testing due to drug
degradation in acidic media.
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